Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335802 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2CYP2C19OPRK1PPARA | |
| SCHEMBL6686370 | 0.93 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2CYP2C19OPRK1ALDH1A1 | |
| SCHEMBL4327529 | 0.91 | MAPT (0.42) | SMN1; SMN2CYP1A2CYP2C19PPARAALDH1A1 | |
| SCHEMBL4331703 | 0.91 | ADRB2 (0.41) | SMN1; SMN2OPRK1PPARAPPARGPPARD | |
| SCHEMBL4335087 | 0.90 | KMT2A (0.41) | SMN1; SMN2CYP1A2CYP2C19PPARAALDH1A1 | |
| SCHEMBL4348461 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CYP2C19OPRK1ALDH1A1 | |
| SCHEMBL4331640 | 0.88 | PPARG (0.42) | SMN1; SMN2CYP1A2CYP2C19PPARAALDH1A1 | |
| SCHEMBL4488496 | 0.87 | PPARA (0.41) | SMN1; SMN2CYP1A2CYP2C19OPRK1PPARA | |
| SCHEMBL4327391 | 0.86 | ALDH1A1 (0.46) | SMN1; SMN2CYP1A2CYP2C19OPRK1PPARA | |
| SCHEMBL4340668 | 0.85 | OPRK1 (0.48) | SMN1; SMN2OPRK1PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | claimed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | claimed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | SMN1; SMN2 3054/4885CYP1A2 1508/4885CYP2C19 2209/4885 |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | PPARG, PPARA, NR3C1 | SMN1; SMN2 4463/4885CYP1A2 1626/4885CYP2C19 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.